Following this activity, participants should be able to: (1) Identify the new neoadjuvant and adjuvant systemic therapy regimens for patients with resectable non-small cell lung cancer (NSCLC). (2) Describe the adverse reactions that may occur with the new neoadjuvant and adjuvant systemic therapy regimens. (3) Educate patients about the new neoadjuvant and adjuvant systemic therapy regimens that are available for those with resectable NSCLC.
- Provider:National Comprehensive Cancer Network
- Activity Link: https://education.nccn.org
- Start Date: 2024-02-27 06:00:00
- End Date: 2024-02-27 06:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: AstraZeneca (Any division) - Amount: 0 - Is Kind Support: False Source: Exelixis - Amount: 0 - Is Kind Support: False Source: GlaxoSmithKline - Amount: 0 - Is Kind Support: False Source: Lantheus - Amount: 0 - Is Kind Support: False Source: Merck (Any division) - Amount: 0 - Is Kind Support: False Source: Novartis Corporation Pharmaceuticals - Amount: 0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest